The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
lnterleukin-2-mediated elimination of the p27Kipl cyclin-dependent kinase inhibitor prevented by rapamycin
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibodies, a laboratory manual
(1989) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(89)90130-3 · Cited by 12,366
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
p21 is a universal inhibitor of cyclin kinases
Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,368
The mechanism of action of cyclosporin A and FK506
Schreiber, S. L., & Crabtree, G. R. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90111-j · Cited by 2,127
Self-citationPolyak, K., Lee, M.-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
Self-citationA mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053
p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21
Toyoshima, H., & Hunter, T. (1994) · Cell · doi:10.1016/0092-8674(94)90573-8 · Cited by 2,043
Polyak, K., Kato, J. Y., Solomon, M. J., Sherr, C. J., Massague, J., Roberts, J. M., & Koff, A. (1994) · Genes & Development · doi:10.1101/gad.8.1.9 · Cited by 1,954
Self-citationSabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., & Snyder, S. H. (1994) · Cell · doi:10.1016/0092-8674(94)90570-3 · Cited by 1,509
Cited by
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Inhibitors of mammalian G1 cyclin-dependent kinases.
Sherr, C. J., & Roberts, J. M. (1995) · Genes & Development · doi:10.1101/gad.9.10.1149 · Cited by 3,243
Self-citationCYCLIN-DEPENDENT KINASES: Engines, Clocks, and Microprocessors
Morgan, D. O. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.261 · Cited by 2,259
TOR, a Central Controller of Cell Growth
Schmelzle, T., & Hall, M. N. (2000) · Cell · doi:10.1016/s0092-8674(00)00117-3 · Cited by 1,924
Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F., & Rolfe, M. (1995) · Science · doi:10.1126/science.7624798 · Cited by 1,817
Nakayama, K., Ishida, N., Shirane, M., Inomata, A., Inoue, T., Shishido, N., Horii, I., Loh, D. Y., & Nakayama, K.-I. (1996) · Cell · doi:10.1016/s0092-8674(00)81237-4 · Cited by 1,547
Fero, M. L., Rivkin, M., Tasch, M., Porter, P., Carow, C. E., Firpo, E., Polyak, K., Tsai, L.-H., Broudy, V., Perlmutter, R. M., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81239-8 · Cited by 1,457
Self-citationNew functional activities for the p21 family of CDK inhibitors.
LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., & Harlow, E. (1997) · Genes & Development · doi:10.1101/gad.11.7.847 · Cited by 1,402
The tor pathway: a target for cancer therapy
Bjornsti, M.-A., & Houghton, P. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1362 · Cited by 1,314
Cheng, M., Olivier, P., Diehl, J. A., Fero, M., Roussel, M. F., Roberts, J. M., & Sherr, C. J. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1571 · Cited by 1,142
Self-citationHuman Cyclin E, a Nuclear Protein Essential for the G1-to-S Phase Transition
Ohtsubo, M., Theodoras, A. M., Schumacher, J., Roberts, J. M., & Pagano, M. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.5.2612 · Cited by 1,148
Self-citationRapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells
Battaglia, M., Stabilini, A., & Roncarolo, M.-G. (2005) · Blood · doi:10.1182/blood-2004-10-3932 · Cited by 1,134
Current development of mTOR inhibitors as anticancer agents
Faivre, S., Kroemer, G., & Raymond, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2062 · Cited by 1,000
Sherr, C. J. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89005-2 · Cited by 980
Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.
Reynisdóttir, I., Polyak, K., Iavarone, A., & Massagué, J. (1995) · Genes & Development · doi:10.1101/gad.9.15.1831 · Cited by 962
Self-citationMatsuoka, S., Edwards, M. C., Bai, C., Parker, S., Zhang, P., Baldini, A., Harper, J. W., & Elledge, S. J. (1995) · Genes & Development · doi:10.1101/gad.9.6.650 · Cited by 952
Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k
Jefferies, H. B. J., Fumagalli, S., Dennis, P. B., Reinhard, C., Pearson, R. B., & Thomas, G. (1997) · The EMBO Journal · doi:10.1093/emboj/16.12.3693 · Cited by 934
Cyclin E-CDK2 is a regulator of p27Kip1.
Sheaff, R. J., Groudine, M., Gordon, M., Roberts, J. M., & Clurman, B. E. (1997) · Genes & Development · doi:10.1101/gad.11.11.1464 · Cited by 911
Self-citationPorter, P. L., Malone, K. E., Heagerty, P. J., Alexander, G. M., Gatti, L. A., Firpo, E. J., Daling, J. R., & Roberts, J. M. (1997) · Nature Medicine · doi:10.1038/nm0297-222 · Cited by 901
Self-citationLee, M. H., Reynisdóttir, I., & Massagué, J. (1995) · Genes & Development · doi:10.1101/gad.9.6.639 · Cited by 889
Self-citationTranslational Control of p27 Kip1 Accumulation During the Cell Cycle
Hengst, L., & Reed, S. I. (1996) · Science · doi:10.1126/science.271.5257.1861 · Cited by 846
Helper T Cell Differentiation Is Controlled by the Cell Cycle
Bird, J. J., Brown, D. R., Mullen, A. C., Moskowitz, N. H., Mahowald, M. A., Sider, J. R., Gajewski, T. F., Wang, C.-R., & Reiner, S. L. (1998) · Immunity · doi:10.1016/s1074-7613(00)80605-6 · Cited by 832
The mTOR Signalling Pathway in Human Cancer
Pópulo, H., Lopes, J. M., & Soares, P. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13021886 · Cited by 830
The murine gene p27Kip1 is haplo-insufficient for tumour suppression
Fero, M. L., Randel, E., Gurley, K. E., Roberts, J. M., & Kemp, C. J. (1998) · Nature · doi:10.1038/24179 · Cited by 784
Self-citationSirolimus: its discovery, biological properties, and mechanism of action
Sehgal, S. N. (2003) · Transplantation Proceedings · doi:10.1016/s0041-1345(03)00211-2 · Cited by 779
Chan, T. O., Rittenhouse, S. E., & Tsichlis, P. N. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.965 · Cited by 737
Brunn, G. J., Williams, J., Sabers, C., Wiederrecht, G., Lawrence, J. C., & Abraham, R. T. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00911.x · Cited by 723
Control of p70 S6 kinase by kinase activity of FRAP in vivo
Brown, E. J., Beal, P. A., Keith, C. T., Chen, J., Bum Shin, T., & Schreiber, S. L. (1995) · Nature · doi:10.1038/377441a0 · Cited by 705
p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells
Sutterlüty, H., Chatelain, E., Marti, A., Wirbelauer, C., Senften, M., Müller, U., & Krek, W. (1999) · Nature Cell Biology · doi:10.1038/12027 · Cited by 700
Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27Kip1
Vlach, J. (1997) · The EMBO Journal · doi:10.1093/emboj/16.17.5334 · Cited by 688
Requirement of p27 Kip1 for Restriction Point Control of the Fibroblast Cell Cycle
Coats, S., Flanagan, W. M., Nourse, J., & Roberts, J. M. (1996) · Science · doi:10.1126/science.272.5263.877 · Cited by 679
Self-citationTranscriptional Regulation of the p21(WAF1/CIP1)Gene
Gartel, A. L., & Tyner, A. L. (1999) · Experimental Cell Research · doi:10.1006/excr.1998.4319 · Cited by 664
Sehgal, S. N. (1998) · Clinical Biochemistry · doi:10.1016/s0009-9120(98)00045-9 · Cited by 663
IMMUNOPHARMACOLOGY OF RAPAMYCIN
Abraham, R. T., & Wiederrecht, G. J. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.483 · Cited by 653
Functional Analysis of Cyclin-Dependent Kinase Inhibitors of Arabidopsis
De Veylder, L., Beeckman, T., Beemster, G. T. S., Krols, L., Terras, F., Landrieu, I., Van Der Schueren, E., Maes, S., Naudts, M., & Inzé, D. (2001) · The Plant Cell · doi:10.1105/tpc.010087 · Cited by 640
Dijkers, P. F., Medema, R. H., Pals, C., Banerji, L., Thomas, N. S. B., Lam, E. W.-F., Burgering, B. M. T., Raaijmakers, J. A. M., Lammers, J.-W. J., Koenderman, L., et al. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.24.9138-9148.2000 · Cited by 617
Lloyd, R. V., Erickson, L. A., Jin, L., Kulig, E., Qian, X., Cheville, J. C., & Scheithauer, B. W. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65277-7 · Cited by 593
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
Hidalgo, M., & Rowinsky, E. K. (2000) · Oncogene · doi:10.1038/sj.onc.1204091 · Cited by 582
Stat5 Is Required for IL-2-Induced Cell Cycle Progression of Peripheral T Cells
Moriggl, R., Topham, D. J., Teglund, S., Sexl, V., McKay, C., Wang, D., Hoffmeyer, A., van Deursen, J., Sangster, M. Y., Bunting, K. D., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80025-4 · Cited by 547
p21 WAF1 is required for butyrate-mediated growth inhibition of human colon cancer cells
Archer, S. Y., Meng, S., Shei, A., & Hodin, R. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6791 · Cited by 535
PIK-Related Kinases: DNA Repair, Recombination, and Cell Cycle Checkpoints
Keith, C. T., & Schreiber, S. L. (1995) · Science · doi:10.1126/science.270.5233.50 · Cited by 518
Koyama, H., Raines, E. W., Bornfeldt, K. E., Roberts, J. M., & Ross, R. (1996) · Cell · doi:10.1016/s0092-8674(00)81801-2 · Cited by 515
Self-citationRapamycin inhibits vascular smooth muscle cell migration.
Poon, M., Marx, S. O., Gallo, R., Badimon, J. J., Taubman, M. B., & Marks, A. R. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119038 · Cited by 511
Molecular Basis of Restenosis and Drug-Eluting Stents
Costa, M. A., & Simon, D. I. (2005) · Circulation · doi:10.1161/01.cir.0000163587.36485.a7 · Cited by 510
Cheng, M., Sexl, V., Sherr, C. J., & Roussel, M. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.1091 · Cited by 496
Yan, Y., Frisén, J., Lee, M. H., Massagué, J., & Barbacid, M. (1997) · Genes & Development · doi:10.1101/gad.11.8.973 · Cited by 493
Self-citationGallo, R., Padurean, A., Jayaraman, T., Marx, S., Roque, M., Adelman, S., Chesebro, J., Fallon, J., Fuster, V., Marks, A., et al. (1999) · Circulation · doi:10.1161/01.cir.99.16.2164 · Cited by 490
Huang, S., Chen, C. S., & Ingber, D. E. (1998) · Molecular Biology of the Cell · doi:10.1091/mbc.9.11.3179 · Cited by 486
Beuvink, I., Boulay, A., Fumagalli, S., Zilbermann, F., Ruetz, S., O’Reilly, T., Natt, F., Hall, J., Lane, H. A., & Thomas, G. (2005) · Cell · doi:10.1016/j.cell.2004.12.040 · Cited by 486
Biology of the Interleukin-2 Receptor
Nelson, B. H., & Willerford, D. M. (1998) · Advances in Immunology · doi:10.1016/s0065-2776(08)60386-7 · Cited by 475
Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F
Leone, G., DeGregori, J., Sears, R., Jakoi, L., & Nevins, J. R. (1997) · Nature · doi:10.1038/387422a0 · Cited by 468
TOR signalling and control of cell growth
Thomas, G., & Hall, M. N. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80078-6 · Cited by 462
MADDIKA, S., ANDE, S., PANIGRAHI, S., PARANJOTHY, T., WEGLARCZYK, K., ZUSE, A., ESHRAGHI, M., MANDA, K., WIECHEC, E., & LOS, M. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.01.003 · Cited by 461
Easton, J. B., & Houghton, P. J. (2006) · Oncogene · doi:10.1038/sj.onc.1209886 · Cited by 459
Zhu, X., Ohtsubo, M., Böhmer, R. M., Roberts, J. M., & Assoian, R. K. (1996) · The Journal of cell biology · doi:10.1083/jcb.133.2.391 · Cited by 453
Self-citationBench to Bedside: The Development of Rapamycin and Its Application to Stent Restenosis
Marx, S. O., & Marks, A. R. (2001) · Circulation · doi:10.1161/01.cir.104.8.852 · Cited by 447
Pearson, R. B., Dennis, P. B., Han, J. W., Williamson, N. A., Kozma, S. C., Wettenhall, R. E., & Thomas, G. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00212.x · Cited by 443
Yu, K., Toral-Barza, L., Discafani, C., Zhang, W. G., Skotnicki, J., Frost, P., & Gibbons, J. J. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080249 · Cited by 420
CTLA-4-Mediated Inhibition of Early Events of T Cell Proliferation
Brunner, M. C., Chambers, C. A., Chan, F. K.-M., Hanke, J., Winoto, A., & Allison, J. P. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.10.5813 · Cited by 419
Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21 CIP1/WAF1 and cyclin D proteins
Yu, Z.-K., Gervais, J. L. M., & Zhang, H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.19.11324 · Cited by 411
Aktas, H., Cai, H., & Cooper, G. M. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.7.3850 · Cited by 410
Phosphatidylinositol 3-Kinase Couples the Interleukin-2 Receptor to the Cell Cycle Regulator E2F
Brennan, P., Babbage, J. W., Burgering, B. M. T., Groner, B., Reif, K., & Cantrell, D. A. (1997) · Immunity · doi:10.1016/s1074-7613(00)80388-x · Cited by 404
Cdk inhibitors in development and cancer
Wade Harper, J., & Elledge, S. J. (1996) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(96)90011-8 · Cited by 399
Pestell, R. G., Albanese, C., Reutens, A. T., Segall, J. E., Lee, R. J., & Arnold, A. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.4.0373 · Cited by 375
Shi, Y., Yan, H., Frost, P., Gera, J., & Lichtenstein, A. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0068 · Cited by 368
RetractedA Signaling Pathway to Translational Control
Brown, E. J., & Schreiber, S. L. (1996) · Cell · doi:10.1016/s0092-8674(00)80125-7 · Cited by 364
PRO- AND ANTI-CANCER EFFECTS OF IMMUNOSUPPRESSIVE AGENTS USED IN ORGAN TRANSPLANTATION
Guba, M., Graeb, C., Jauch, K.-W., & Geissler, E. K. (2004) · Transplantation · doi:10.1097/01.tp.0000120181.89206.54 · Cited by 360
Mechanism of action of the immunosuppressant rapamycin
Dumont, F. J., & Su, Q. (1995) · Life Sciences · doi:10.1016/0024-3205(95)02233-3 · Cited by 358
Akt-dependent Phosphorylation of p27Kip1Promotes Binding to 14-3-3 and Cytoplasmic Localization
Fujita, N., Sato, S., Katayama, K., & Tsuruo, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203668200 · Cited by 358
Fredersdorf, S., Burns, J., Milne, A. M., Packham, G., Fallis, L., Gillett, C. E., Royds, J. A., Peston, D., Hall, P. A., Hanby, A. M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6380 · Cited by 357
RAS and RHO GTPases in G1-phase cell-cycle regulation
Coleman, M. L., Marshall, C. J., & Olson, M. F. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1365 · Cited by 355
Vascular Smooth Muscle Cell Proliferation in Restenosis
Marx, S. O., Totary-Jain, H., & Marks, A. R. (2011) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.110.957332 · Cited by 354
Hashemolhosseini, S., Nagamine, Y., Morley, S. J., Desrivières, S., Mercep, L., & Ferrari, S. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14424 · Cited by 342
Reynisdóttir, I., & Massagué, J. (1997) · Genes & Development · doi:10.1101/gad.11.4.492 · Cited by 333
Signaling by Target of Rapamycin Proteins in Cell Growth Control
Inoki, K., Ouyang, H., Li, Y., & Guan, K.-L. (2005) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.69.1.79-100.2005 · Cited by 330
Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation.
Linette, G. P., Li, Y., Roth, K., & Korsmeyer, S. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9545 · Cited by 329
JNK is required for effector T-cell function but not for T-cell activation
Dong, C., Yang, D. D., Tournier, C., Whitmarsh, A. J., Xu, J., Davis, R. J., & Flavell, R. A. (2000) · Nature · doi:10.1038/35011091 · Cited by 328
Durand, B. (1997) · The EMBO Journal · doi:10.1093/emboj/16.2.306 · Cited by 325
The Prognostic Significance of Altered Cyclin-Dependent Kinase Inhibitors in Human Cancer
Tsihlias, M., Kapusta, M., & Slingerland, M. (1999) · Annual Review of Medicine · doi:10.1146/annurev.med.50.1.401 · Cited by 319
Chinni, S. R., Li, Y., Upadhyay, S., Koppolu, P. K., & Sarkar, F. H. (2001) · Oncogene · doi:10.1038/sj.onc.1204365 · Cited by 315
Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc.
Vlach, J., Hennecke, S., Alevizopoulos, K., Conti, D., & Amati, B. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01050.x · Cited by 313
Missero, C., Di Cunto, F., Kiyokawa, H., Koff, A., & Dotto, G. P. (1996) · Genes & Development · doi:10.1101/gad.10.23.3065 · Cited by 312
Cool, C. D., Stewart, J. S., Werahera, P., Miller, G. J., Williams, R. L., Voelkel, N. F., & Tuder, R. M. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65137-1 · Cited by 309
Philipp-Staheli, J., Payne, S. R., & Kemp, C. J. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5143 · Cited by 293
Kahan, B. D., Podbielski, J., Napoli, K. L., Katz, S. M., Meier-Kriesche, H.-U., & Van Buren, C. T. (1998) · Transplantation · doi:10.1097/00007890-199810270-00013 · Cited by 288
Cyclin dependent kinase regulation
Lees, E. (1995) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(95)80060-3 · Cited by 285
Cell Cycle Progression: New Therapeutic Target for Vascular Proliferative Disease
Braun-Dullaeus, R. C., Mann, M. J., & Dzau, V. J. (1998) · Circulation · doi:10.1161/01.cir.98.1.82 · Cited by 285
Blain, S. W., Montalvo, E., & Massagué, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.41.25863 · Cited by 279
Self-citationMultiple functions of p27Kip1 and its alterations in tumor cells: a review
Sgambato, A., Cittadini, A., Faraglia, B., & Weinstein, I. B. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200004)183:1<18::aid-jcp3>3.0.co;2-s · Cited by 276
Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation
Dennis, P. B., Fumagalli, S., & Thomas, G. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80007-0 · Cited by 275
Porter, P. L., El-Bastawissi, A. Y., Mandelson, M. T., Lin, M. G., Khalid, N., Watney, E. A., Cousens, L., White, D., Taplin, S., & White, E. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.23.2020 · Cited by 264
Phosphorylation of p27 on Serine 10 Is Required for Its Binding to CRM1 and Nuclear Export
Ishida, N., Hara, T., Kamura, T., Yoshida, M., Nakayama, K., & Nakayama, K. I. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c100762200 · Cited by 264
Sundrud, M. S., Torres, V. J., Unutmaz, D., & Cover, T. L. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401528101 · Cited by 262
Murgia, M. G., Jordan, S., & Kahan, B. D. (1996) · Kidney International · doi:10.1038/ki.1996.28 · Cited by 261
mTOR-Raptor Binds and Activates SGK1 to Regulate p27 Phosphorylation
Hong, F., Larrea, M. D., Doughty, C., Kwiatkowski, D. J., Squillace, R., & Slingerland, J. M. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.027 · Cited by 260
The multiple facets of mTOR in immunity
Weichhart, T., & Säemann, M. D. (2009) · Trends in Immunology · doi:10.1016/j.it.2009.02.002 · Cited by 259
Curcumin inhibits the mammalian target of rapamycin‐mediated signaling pathways in cancer cells
Beevers, C. S., Li, F., Liu, L., & Huang, S. (2006) · International Journal of Cancer · doi:10.1002/ijc.21932 · Cited by 256
Rapamycin: an anti-cancer immunosuppressant?
Law, B. K. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.09.009 · Cited by 252
p107 uses a p21CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F.
Zhu, L., Harlow, E., & Dynlacht, B. D. (1995) · Genes & Development · doi:10.1101/gad.9.14.1740 · Cited by 252
Cholesterol trafficking is required for mTOR activation in endothelial cells
Xu, J., Dang, Y., Ren, Y. R., & Liu, J. O. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910872107 · Cited by 209
Metadata
- Authors
- Nourse, J., Firpo, E., Flanagan, W. M., Coats, S., Polyak, K., Lee, M.-H., Massague, J., Crabtree, G. R., & Roberts, J. M.
- Venue
- Nature
- Published
- 1994-12
- Volume
- 372
- Issue
- 6506
- Pages
- 570-573
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1980720313
- Cited by
- 889
- References
- 23
- FWCI
- 23.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.